Syndicate / NetworkBlueLotus Ventures
StagesPre-Seed
SectorsSaaS / Enterprise, Fintech, Consumer / D2C · Early-stage builders, Founder-led / operator capital
Ticket$100K – $150K
77 Capital backs early-stage Indian startups at Pre-Seed and Seed stages, focusing on SaaS, B2B marketplaces, FinTech, and HealthTech through a syndicate model that brings together aligned capital and operator networks.
Key signals founders use to decide if this investor is worth a conversation.
Stages and sectors this investor typically backs.
Themes this investor is mapped to across the VC Dekho directory.
77 Capital backs early-stage Indian startups at Pre-Seed and Seed stages, focusing on SaaS, B2B marketplaces, FinTech, and HealthTech through a syndicate model that brings together aligned capital and operator networks.
6 companies mapped to this fund.
Background and context for founders evaluating this investor.
77 Capital is an Indian investment syndicate that writes cheques of USD 75,000 to 100,000 into Pre-Seed and Seed stage startups. Its portfolio reflects a clear conviction around B2B software and infrastructure businesses, with investments spanning enterprise and SMB SaaS, B2B marketplaces, fintech, and health tech. Companies like M2P and Hyperface signal comfort with fintech infrastructure and API-led business models, while Clinikally and Fego point to interest in digital health and consumer wellness built on strong tech foundations. Vidyut Tech and Mewt further demonstrate a pattern of backing asset-light, scalable Indian startups solving real enterprise or platform problems. As a syndicate, 77 Capital offers founders more than just capital; the model typically means co-investors and domain-relevant angels come in alongside the lead, which can be valuable for startups seeking both money and market access. Founders pitching to 77 Capital should be prepared to articulate clear unit economics, a defensible B2B go-to-market strategy, and a path to scalable revenue. The typical entry point is early enough to help shape the company, making a crisp product narrative and a strong founding team the most important factors in the conversation.
Its portfolio reflects a clear conviction around B2B software and infrastructure businesses, with investments spanning enterprise and SMB SaaS, B2B marketplaces, fintech, and health tech.
Mewt, Fego, Clinikally, Vidyut Tech, M2P, Hyperface
Tend to turnaround quickly, primarily calls with the founders + 3rd party due diligence (if required)
Data confidence: Unverified – inferred
Partners and principals mapped to this fund in the directory.
Other funds that overlap on stage, sector, or thesis.
Jump into stage, sector, and thesis mapped to this fund.